Esophageal Cancer (EsC)
Conditions
Brief summary
This is a prospective, single-center, non-inferiority randomized controlled trial designed to evaluate the perioperative safety and feasibility of non-intubated spontaneous ventilation anesthesia (NIV) compared to conventional intubated mechanical ventilation anesthesia (IMV) in patients undergoing thoracoscopic esophagectomy for esophageal cancer. The study will be conducted at the First Affiliated Hospital of Guangzhou Medical University and aims to assess whether the non-intubated approach can offer comparable or better outcomes in terms of intraoperative and postoperative complications, anesthetic drug consumption, recovery parameters, and overall postoperative rehabilitation. Eligible patients aged 18 to 75 years with resectable middle or lower thoracic esophageal squamous cell carcinoma or adenocarcinoma (stage I-III) will be randomly assigned (1:1) to receive either NIV using a laryngeal mask airway or IMV with a double-lumen endotracheal tube. Both groups will undergo the same thoracoscopic and laparoscopic surgical procedures, and anesthesia will be managed with standardized protocols. The primary outcome is the incidence of intraoperative and postoperative complications, including hypoxemia, hypercapnia, respiratory failure, and the need for conversion to intubation. Secondary outcomes include anesthetic drug dosage, intraoperative hemodynamic stability, postoperative pain scores, time to ambulation, length of hospital stay, and 30-day readmission rate. This trial complies with the Declaration of Helsinki. Written informed consent will be obtained from all participants prior to enrollment.
Interventions
Non-intubated spontaneous ventilation anesthesia
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Age between 18 and 75 years * Diagnosed with resectable middle or lower thoracic esophageal squamous cell carcinoma or adenocarcinoma (clinical stage I-III) * Scheduled to undergo thoracoscopic esophagectomy * American Society of Anesthesiologists (ASA) score ≤ III * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 * Preoperative pulmonary function test with FEV₁ ≥ 50% predicted * Written informed consent obtained
Exclusion criteria
* Severe risk of aspiration due to reflux, gastric retention, or hiatal hernia * Body mass index (BMI) ≥ 30 kg/m² * Extensive pleural adhesions discovered preoperatively * History of upper thoracic or intrathoracic surgery * Pregnancy or lactation * Known allergy or intolerance to anesthetic agents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of intraoperative and postoperative complications | From anesthesia induction to 30 days postoperatively | Composite incidence of complications occurring intraoperatively or within 30 days after surgery, including hypoxemia (SpO₂ \< 90% for \>1 minute), hypercapnia (PaCO₂ ≥ 65 mmHg), conversion to intubation (in the non-intubated group), severe arrhythmia, hemodynamic instability, postoperative pulmonary infection, anastomotic leakage, bleeding, pneumothorax, respiratory failure, and reintubation. |
Outcome results
None listed